SEARCH

SEARCH BY CITATION

References

  • 1
    NIH Consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 146.
  • 2
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875881.
  • 3
    Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. HEPATOLOGY 1998; 28: 11211127.
  • 4
    Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783787.
  • 5
    McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. HEPATOLOGY 2002; 35: 688693.
  • 6
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 7
    Ross RS, Viazov SO, Hoffmann S, Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal 2001; 15: 308313.
  • 8
    Gorrin G, Friesenhahn M, Lin P, Sanders M, Pollner R, Eguchi B, et al. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. J Clin Microbiol 2003; 41: 310317.
  • 9
    Hendricks DA, Friesenhahn M, Tanimoto L, Goergen B, Dodge D, Comanor L. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003; 41: 651656.
  • 10
    Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. HEPATOLOGY 2006; 44: 360367.
  • 11
    Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. HEPATOLOGY 2000; 32: 818823.
  • 12
    Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol 2001; 39: 28502855.
  • 13
    Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C, et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001; 96: 29682972.
    Direct Link:
  • 14
    Gerotto M, Pero FD, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006; 44: 8387.
  • 15
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472492.
  • 16
    Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol 2004; 42: 421425.
  • 17
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 10151023.
  • 18
    Kadam JS, Gonzalez SA, Ahmed F, Menezes A, Jacobson IM. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin. Dig Dis Sci 2007; 52: 25252530.
  • 19
    Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. HEPATOLOGY 2005; 41: 106114.